DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic retinopathy patient populations covering 171 countries and more…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic macular edema patient populations covering 171 countries and more…
The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to…
Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as biguanides, insulin secretagogues (…
MARKET OUTLOOK The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, together with conventional treatments, makes…
MARKET OUTLOOKRelapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage…
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure (CHF) cases. Our understanding of the pathophysiology of the disease has improved…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23…
Erythropoiesis-stimulating agent (ESA) biosimilars entered the European market a decade ago, but only one ESA—Retacrit—has launched in the United States, and it did not launch until November…
DRG Epidemiology’s coverage of Acute Lymphoblastic Leukemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Multiple well-established therapies are available to treat Crohn’s disease (CD). In particular, the most widely used biologics—the TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/…
Owing to the various etiologies of the disease and differences in presentation, management of FSGS needs to be individualized. As the nephrotic syndrome increases the risk of worse outcomes, RAAS…
Hypertrophic cardiomyopathy is disease characterized by thickening of the myocardium, leading to left ventricular hypertrophy. The disease commonly has a genetic underpinning, and is often …